Shawn Schiller

Company: Foghorn Therapeutics

Job title: Director

Seminars:

Panel Discussion: Assessing Targeted Protein Degradation’s Ability to be Both Selective & Safe 9:45 am

How much progress has been made in identifying and utilising tissue-sparing E3 ligases? Are there more ligases to find? How do we effectively identify them? What does existing off-target safety data tell us about degraders’ behaviour in clinic? Are Molecular Glues a ‘safer’ option? Are there other ‘TACs’ that have potential to be safer due…Read more

day: Conference Day One

Discovery, Characterisation, & Optimisation of CBP Selective Degraders 8:45 am

Identifying and optimizing potent, selective degraders of CBP to address mutant EP300 Cancers Spotlighting demonstrated, robust activity in preclinical pk/pd and efficacy models Demonstrating no observed thrombocytopenia in mice at pharmacologically relevant dosesRead more

day: Conference Day One